ALN-PCSSC ( DrugBank: ALN-PCSsc )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
79家族性高コレステロール血症(ホモ接合体)2

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 145 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003376-49-NL
(EUCTR)
20/06/201718/01/2017A study to evaluate the effect of ALN-PCSSC treatment in patients with Homozygous Familial HypercholesterolemiaAn Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia - ORION-2 Homozygous Familial Hypercholesterolemia
MedDRA version: 19.1;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: ALN-PCSSC
Product Code: ALN-PCSSC
INN or Proposed INN: ALN-60212
Other descriptive name: ALN-60212
The Medicines CompanyNULLNot RecruitingFemale: yes
Male: yes
10Phase 2United States;South Africa;Netherlands
2NCT02963311
(ClinicalTrials.gov)
December 13, 201610/11/2016A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial HypercholesterolemiaDrug: ALN-PCSSC;Drug: Standard of CareThe Medicines CompanyNULLCompleted12 YearsN/AAll9Phase 2United States;Netherlands;South Africa